VTGN Stock Overview
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Vistagen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$24.71 |
| 52 Week Low | US$1.62 |
| Beta | 0.81 |
| 1 Month Change | 8.05% |
| 3 Month Change | -3.09% |
| 1 Year Change | 14.61% |
| 3 Year Change | -93.50% |
| 5 Year Change | -72.03% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10
VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16
VistaGen Therapeutics regains Nasdaq listing compliance
Jan 06VistaGen Therapeutics slumps in after hours trade on underwritten public offering
Dec 17VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines
Nov 12Shareholder Returns
| VTGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | 14.6% | 0.9% | 21.9% |
Return vs Industry: VTGN exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: VTGN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| VTGN volatility | |
|---|---|
| VTGN Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTGN has not had significant price volatility in the past 3 months.
Volatility Over Time: VTGN's weekly volatility has decreased from 97% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 37 | Shawn Singh | www.vistagen.com |
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.
Vistagen Therapeutics, Inc. Fundamentals Summary
| VTGN fundamental statistics | |
|---|---|
| Market cap | US$127.02m |
| Earnings (TTM) | -US$32.07m |
| Revenue (TTM) | US$1.04m |
121.9x
P/S Ratio-4.0x
P/E RatioIs VTGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTGN income statement (TTM) | |
|---|---|
| Revenue | US$1.04m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.04m |
| Other Expenses | US$33.11m |
| Earnings | -US$32.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,076.62% |
| Debt/Equity Ratio | 0% |
How did VTGN perform over the long term?
See historical performance and comparison